ROBIN HOWARD W (President & CEO) sold 26.7% of their position (20K shares) of NEKTAR THERAPEUTICS on the open market
Open‑market sale worth $1.22M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 6/18/2026ACC: 0001193125-26-276236
DirectorOfficer· President & CEO
Since Aug 2018
-20K
Net shares
Net seller
$1.22M
Total sold
4
Open market trades
0B · 4S
4
Total transactions
20K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−5.30K
Price / share
$59.97
Trade value
$318.02K
% of position
7.1%
6/16/2026
75.05K→69.74K
Common Stock
Direct
Shares
−4.70K
Price / share
$60.71
Trade value
$285.15K
% of position
6.7%
6/16/2026
69.74K→65.05K
Common Stock
Direct
Shares
−5.50K
Price / share
$60.81
Trade value
$334.45K
% of position
8.5%
6/17/2026
65.05K→59.55K
Common Stock
Direct
Shares
−4.50K
Price / share
$61.65
Trade value
$277.43K
% of position
7.6%
6/17/2026
59.55K→55.05K
Total
Net shares
−20K
Net value
-$1.22M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/16/2026 | S · Sale | −5.30K | $59.97 | $318.02K | 7.1% | 75.05K | 69.74K |
| Common Stock Direct | 6/16/2026 | S · Sale | −4.70K | $60.71 | $285.15K | 6.7% | 69.74K | 65.05K |
| Common Stock Direct | 6/17/2026 | S · Sale | −5.50K | $60.81 | $334.45K | 8.5% | 65.05K | 59.55K |
| Common Stock Direct | 6/17/2026 | S · Sale | −4.50K | $61.65 | $277.43K | 7.6% | 59.55K | 55.05K |
| Total | −20K | -$1.22M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned28.00
Total
28.00 indirect28.00
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 28.00 | Indirect |
| Total | 28.00 | 28.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported